Authors


Jeremie Calais, MD, PhD

Latest:

Jeremie Calais, MD, highlights study of PSMA-PET vs bone scan in metastatic prostate cancer

“On a lesion level, there were still more lesions detected with PSMA-PET, but not on a patient level,” says Jeremie Calais, MD, PhD.


David S. Morris, MD, FACS

Latest:

Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Overview

Panelists discuss how metastatic castration-sensitive prostate cancer (mCSPC) is managed with a combination of androgen deprivation therapy, chemotherapy, and novel agents like such as abiraterone and enzalutamide, aiming to improve survival outcomes while addressing the disease's high metastatic burden.


Megan Hollasch

Latest:

Understanding molecular phenotypes in RCC may help drive treatment decisions

Benjamin L. Maughan, MD, PharmD, highlights key studies presented at the 2024 ASCO Annual Meeting regarding biomarkers and the evolution of first-line treatments in renal cell carcinoma.


GenesisCare

Latest:

GenesisCare Enrolls First Patients to SpaceOAR Vue Hydrogel Global Clinical Trial

For the first time, the trial will examine the efficacy of SpaceOAR Vue Hydrogel in reducing late gastrointestinal toxicity and improving the quality of life in patients receiving stereotactic body radiotherapy for the treatment of prostate cancer.


Kelli Gross, MD

Latest:

Expert Forum: Fertility after exogenous testosterone replacement

Treatment of azoospermia after exogenous testosterone use may require aggressive medical therapy, according to Kelli Gross, MD.


Varun Sundaram, MD

Latest:

Future Landscape of Prostate Cancer and Rectal Spacers

The expert panel concludes their discussion with a look toward the future of prostate cancer treatment and the evolving role of rectal spacers.


Oliver Sartor, MD

Latest:

Unmet Needs and Clinical Challenges for PSMA Imaging

Oliver Sartor, MD, discusses how unmet needs and clinical challenges for PSMA imaging in prostate cancer patients include standardizing interpretation criteria, addressing false negatives in certain tumor phenotypes, improving accessibility and cost-effectiveness, and developing strategies for patients with low PSMA expression or PSMA-negative disease.


Jesse Persily, MD

Latest:

Upper tract urothelial carcinoma: An in-depth review for urologists

"On-going innovation will continue to drive UTUC management forward, and with it will come on-going challenges of how to best study a relatively rare disease," write the authors.


Kara Hartl, MD

Latest:

Hybrid approach to telehealth effective in rural communities

“A hybrid telehealth approach expands access to specialized care, reduces travel burdens, promotes timely interventions, and enables continuous management of health conditions,” writes Kara Hartl, MD.


Angelo A. Baccala, MD

Latest:

Unmet Needs and Treatment Gaps in Prostate Cancer

The panel concludes by addressing unmet needs in prostate cancer management, with a particular focus on improving risk stratification methods.


Lawrence Karsh, MD, FACS

Latest:

ADT Treatment Considerations and Unmet Needs in Prostate Cancer

Experts on prostate cancer discuss current unmet needs in the therapeutic landscape and outline treatment considerations for patients receiving androgen deprivation therapy.


Jay D. Raman, MD, FACS

Latest:

Strategies to mitigate impact of intravenous ICM shortage

"The global shortage of ICM has necessitated rapid adaptation of workflows and clinical pathways, which are particularly important for practicing urologists who are evaluating patients for hematuria," write Yair Lotan, MD, and colleagues.


Oron Afek

Latest:

Expert examines tech-driven burnout in healthcare

“Health care technology has largely failed to deliver on its promise to make the management of patient care simpler, easier, and less stressful for clinicians,” writes Oron Afek.


Eric Demers

Latest:

What role can automation play in solving the prior authorization issue?

If automation can enhance efficiency and reduce provider dissatisfaction while improving patient health, there’s a strong case for introducing automation into the mix, writes industry expert Eric Demers.


Jim Brady

Latest:

Tax deduction can offset your practice’s cost for new equipment and technology

Section 179 of the IRS Tax Code allows businesses to deduct up to the full purchase price of qualified equipment, technology, software, and other qualifying purchases from their taxes within the same tax year.


Lisa Taylor

Latest:

Expert explains the crucial role of interoperability in medical billing

"Without interoperability, electronic insurance billing would be nearly impossible. Insurance payers, healthcare providers and claim clearinghouses all rely on interoperability at their core," writes Lisa Taylor.


MidLantic Urology

Latest:

Dean Laganosky, M.D., named Urology Trailblazer for 2024

This prestigious recognition is given to one urologist or administrator each year who has significantly contributed to the field of urology within the first ten years of their practice.


Abdul J. Roberts, Esq

Latest:

Trends in coding audits and what physicians can expect

Recent trends in medical audits and what physicians can expect with the CMS changes in 2021 to the documentation of E/M codes.


Michael J. Kennelly, MD, FPMRS, FACS

Latest:

Enhancing Patient-Centric Management in OAB in 2024 and Beyond

Panelists conclude their discussion by reflecting on key learnings and sharing advice for patient-centric management in overactive bladder (OAB) treatment, specifically focusing on effective communication and overlooked aspects of patient care. They offer guidance to other providers on enhancing patient experiences, particularly with procedures like Botox. The episode wraps up with each expert sharing their final thoughts and anticipations for advancements in OAB treatment in 2024, highlighting their commitment to addressing patient needs in this evolving field.


Christine Ibilibor, MD, MSc

Latest:

The effects of exercise before and after a prostate cancer diagnosis

"This article serves as a summary of the literature published in the past 3 years, documenting the impact of exercise and physical activity on prostate cancer development and on cancer-specific, treatment-related, and patient-reported outcomes," writes Christine Ibilibor, MD, MSc.


Ryan Scott

Latest:

Dr. Xu on why biomarkers are needed for individualized treatment approaches in RCC

“Systemic therapy for RCC has changed very quickly. Every year, it's exciting to see that we're getting new developments, new drug approvals, and changes in the standard of care,” says Wenxin (Vincent) Xu, MD.


Lesley H. Souter, PhD

Latest:

Strategies to mitigate impact of intravenous ICM shortage

"The global shortage of ICM has necessitated rapid adaptation of workflows and clinical pathways, which are particularly important for practicing urologists who are evaluating patients for hematuria," write Yair Lotan, MD, and colleagues.


Amir Soltani-Tehrani, MD

Latest:

Lymph nodes in bladder cancer: Past, present, and future

"Based on the LEA and S1011 trials, it has become clear that patients do not benefit from an extended LND, and a standard bilateral pelvic LND is the standard of care," write Amir Soltani-Tehrani, MD, and Kamal S. Pohar, MD.


Dave S. Gilreath, CFP, Edward “JR” Humphreys, CFA, CAIA

Latest:

UT Money Matters: Are REITs right for your portfolio?

Real estate investment trusts (REITs) offer an alternative asset to stocks or bonds that provide a convenient way to get income from rental properties without the risks and commitment of owning directly.


David Morris, MD, FACS

Latest:

Optimizing Care Collaboration in Advanced Prostate Cancer

Explore strategies for seamless coordination between urologists and medical oncologists to ensure uninterrupted, patient-focused care in prostate cancer treatment.


Jeffrey Ferguson, MD

Latest:

Unmet Needs and Treatment Gaps in Prostate Cancer

The panel concludes by addressing unmet needs in prostate cancer management, with a particular focus on improving risk stratification methods.


Aaron Fleishman, MPH

Latest:

Emulating target trials using observational evidence to inform clinical decision-making

"The emulation framework lends the design and conduct of observational analyses some of the rigor required for the planning of a randomized trial. In doing so, it provides an innovative and principled approach to improve the evidence base on the comparative effectiveness of interventions," writes Boris Gershman, MD, and Aaron Fleishman, MPH.


Gary Steinberg, MD, FACS

Latest:

AUA 2024: Key Takeaways & Future of NMIBC Management

Gary D. Steinberg, MD, summarizes his major takeaway from the AUA 2024 conference and shares his insights on the potentially practice-changing developments he anticipates in the near future for the management of non-muscle-invasive bladder cancer (NMIBC).


MUSC Health

Latest:

Prostate cancer survivor treated at MUSC shares his story

Prostate cancer survivor Larry Ferguson, DMD, participated in a clinical trial at MUSC Hollings Cancer Center.


Jordan Rosenfeld

Latest:

Advice for limiting malpractice insurance costs

Expert advice for physicians seeking new coverage.

© 2024 MJH Life Sciences

All rights reserved.